Pharmacokinetics, Pharmacodynamics and Antiviral Efficacy of the MEK Inhibitor Zapnometinib in Animal Models and in Humans.

Autor: Koch-Heier J; Department of Immunology, Interfaculty Institute for Cell Biology, Eberhard Karls University Tuebingen, Tuebingen, Germany.; Atriva Therapeutics GmbH, Tuebingen, Germany., Schönsiegel A; Department of Immunology, Interfaculty Institute for Cell Biology, Eberhard Karls University Tuebingen, Tuebingen, Germany.; Atriva Therapeutics GmbH, Tuebingen, Germany., Waidele LM; Department of Immunology, Interfaculty Institute for Cell Biology, Eberhard Karls University Tuebingen, Tuebingen, Germany.; Atriva Therapeutics GmbH, Tuebingen, Germany., Volk J; Department of Immunology, Interfaculty Institute for Cell Biology, Eberhard Karls University Tuebingen, Tuebingen, Germany.; Atriva Therapeutics GmbH, Tuebingen, Germany., Füll Y; Atriva Therapeutics GmbH, Tuebingen, Germany., Wallasch C; Atriva Therapeutics GmbH, Tuebingen, Germany., Canisius S; Atriva Therapeutics GmbH, Tuebingen, Germany., Burnet M; Synovo GmbH, Tuebingen, Germany., Planz O; Department of Immunology, Interfaculty Institute for Cell Biology, Eberhard Karls University Tuebingen, Tuebingen, Germany.; Atriva Therapeutics GmbH, Tuebingen, Germany.

Publikováno v: Frontiers in pharmacology [Front Pharmacol] 2022 Jun 15; Vol. 13, pp. 893635. Date of Electronic Publication: 2022 Jun 15 (Print Publication: 2022).